{"name":"Yingu Pharmaceutical Co., Ltd","slug":"yingu-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Bencycloquidium Bromide Nasal Spray","genericName":"Bencycloquidium Bromide Nasal Spray","slug":"bencycloquidium-bromide-nasal-spray","indication":"Allergic rhinitis with rhinorrhea","status":"marketed"},{"name":"Mometasone Furoate Aqueous Nasal Spray","genericName":"Mometasone Furoate Aqueous Nasal Spray","slug":"mometasone-furoate-aqueous-nasal-spray","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Bencycloquidium Bromide Nasal Spray","genericName":"Bencycloquidium Bromide Nasal Spray","slug":"bencycloquidium-bromide-nasal-spray","phase":"marketed","mechanism":"Bencycloquidium bromide is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce nasal secretions and congestion.","indications":["Allergic rhinitis with rhinorrhea","Vasomotor rhinitis"],"catalyst":""},{"name":"Mometasone Furoate Aqueous Nasal Spray","genericName":"Mometasone Furoate Aqueous Nasal Spray","slug":"mometasone-furoate-aqueous-nasal-spray","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOaU5fWi1lNUE5QUpxdDBfdmNYUnhfa0lucXJ5d3F4UnRvM3ljT2pzdVVRNHY3TUhLNDBOQ0hHdk5xOFN2Y0pZaTlCWGRVZ2R1VzZ1YWxldkhrdUJRdTBJZ0tRbDlSRXA2ak15ektmemhvNFMycG16eXVNYWdROXRnZTlVQnRJNEthaDRXRTdVNFk5ZjRa?oc=5","date":"2026-04-02","type":"pipeline","source":"openPR.com","summary":"Allergic Rhinitis Market: Strong Pharma Growth Forecast Through 2034 - DelveInsight - openPR.com","headline":"Allergic Rhinitis Market: Strong Pharma Growth Forecast Through 2034 - DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPRVd6WXpfckdJZGoxTUJaOGRyaXpqcXgzX1RSS0xmRFp6MEx5NUJqQkZfaW5rQTRSMDBJWG9mZ2ZnQUMtZl9WTkhoNFdiZ1hyekYxUXczTzhhZlZtd1ZsSWg0d2plTnZPU3pUY0xsR0g0MnQ2OGUtcXdzOExuaEhJdDNoMGRLZ0owUzZ0WHFweHZRZnlrODBud0htTzUwcndEb1A2QzdQb3dOTFBMSGM3MmJCZEVmZmthNmdibmN6MnBNYmtFLTdNSzl3X2FZSmUyN3lNemFaQ1JmNnI2dU9ZLWVMSFgyQXlzU0thSGl3ZWpDbklKbjlpelA4WEFhQTlxMzIyYlB3cHRGNWhDRnVmb0Z0NlVOSnFSU3B0Zzh0eFgtbWlGTEtlMURhNjFUd3dFMEow?oc=5","date":"2025-07-21","type":"pipeline","source":"GlobeNewswire","summary":"Cutaneous T-cell Lymphoma Market Anticipates Impressive - GlobeNewswire","headline":"Cutaneous T-cell Lymphoma Market Anticipates Impressive","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNVmxTVFJBV3RLNGJPVkQzTVFZYjNUSU9wYk1PMHlRVkU0TnNITDRBa1BJUlFEZ1dZeHUyNmRhTG1YRWUwb3dMSE9UWHFOX0E2bEgwREVacHJPWlg0bk1IYzdXVWwxMHpMMEJoN3o0U3JHS0UyNklmTS0zYTJsRXVvMmF1SU5nRkFHaXR4bGhjS2pRellDenAyUXZYa1dwbG9Q?oc=5","date":"2025-04-03","type":"regulatory","source":"Targeted Oncology","summary":"FDA OKs Phase 3 Study of Linperlisib in Peripheral T-Cell Lymphoma - Targeted Oncology","headline":"FDA OKs Phase 3 Study of Linperlisib in Peripheral T-Cell Lymphoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE5QT0JZU0kzaU5qTUZSaGtuTXZsMVFaN3d6NVpJREdBeTEwUXZPOUh2UDV0YTJqZmlFUXNfNFNrTWQydjJ0Z205VXlPdkxrV2lFYXl1U2hHUXpHY2tCS1FfaEt2aG9wVmF4RmNTNGFrOGlhcFJrTmc?oc=5","date":"2025-04-02","type":"regulatory","source":"Clinical Trials Arena","summary":"Yingli Pharma gains FDA approval for Phase III trial of r/r PTCL drug candidate - Clinical Trials Arena","headline":"Yingli Pharma gains FDA approval for Phase III trial of r/r PTCL drug candidate","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQOG5sZEpjUzZkYzhvUUl0YVh3QjFuTVdsREQ0SnB0X0trN0NEbmw0Z2ZnZ296dWhQalE1OFNIdHZGYUZ2Q0lIQTQxUElFNWlnbU11dFJWcVQ5Wk12ZWpQaGJyVUZSWnB4NFA0ZXR3TXNIZVNXTFNGb0MtMEl2OC1BaE1NV2xKVnhHM0xJYmpnNVZ5eWUxbDlFczdDaGR3RGV2QlQ0THZkM0RuZ29qZW1kMjcyVGI?oc=5","date":"2024-04-12","type":"pipeline","source":"Seeking Alpha","summary":"Revolution Medicines: An Expensive Shot At A Massive Market Opportunity (NASDAQ:RVMD) - Seeking Alpha","headline":"Revolution Medicines: An Expensive Shot At A Massive Market Opportunity (NASDAQ:RVMD)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQdzljUS1hQ1dCd3ZVVEJLSE1PVjJZRTNJbmVIMkZrVl9sVUxFc2h0TEZkTHJoLWRYUFIwdC1pMi1MREtwVUM0azFCSTNNRlgwQ0N6dGpobnJ6UER1ZGhmdnVSWlppYm80Z1NOUEd4THk3MEZnZ2NOSWE5QVhrS2dGQm9MdEFKN3VPMzRHWmVsaHVmbDUtS3dqa1hSS2syRF9Xeng4RkRkMk1ZZmRTSUhJMERfLUhsN2NkbTdxVGczV25mZWNZbjZ3N1ZsaU5hVm1RUTFQLXJ2YndiLWZWME5sMGY1VUdpUHRTTElULUdBdmdmMUN4aFdkTkduUEhFOERHSEVZOHUyT2M?oc=5","date":"2022-05-26","type":"trial","source":"GlobeNewswire","summary":"Yingli Pharma Doses First US Patient in Phase 1 Study of YL-13027 for Patients with Advanced Solid Tumors - GlobeNewswire","headline":"Yingli Pharma Doses First US Patient in Phase 1 Study of YL-13027 for Patients with Advanced Solid Tumors","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}